Skip to main content

Table 2 IncobotulinumtoxinA dosing at each treatment cycle

From: IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability

No. of Treatment cycle/patientParticipants, nNo. of muscles injected; mean (SD) [range]IncobotulinumtoxinA dose injected, U; mean (SD) (range)IncobotulinumtoxinA dose injected, U/kg;mean (SD) [range]Maximum total dose recommendeda, U; mean (SD) [range]Percentage of maximum total dose injectedb, %; mean (SD) [range]
1692.4 (1.2) [1–5]191.7 (126.2) [40–600]8.5 (5.4) [0.7–24]323.3 (82.9) [160–400]59.2 (33.2) [10–150]
2522.6 (1.6) [1–7]c179.2 (114.0) [40–420]7.6 (4.9) [0.7–17.5]338.1 (77.5) [176–400]53.4 (29.6) [10–109]
3333.0 (1.6) [1–7]d225.8 (130.4) [40–480]8.6 (5.2) [0.7–17.6]356.1 (67.1) [192–400]63.2 (31.8) [10–120]
4213.4 (1.7) [1–7]258.6 (128.6) [80–480]9.3 (4.8) [3–15.7]363.5 (65.4) [192–400]71.5 (31.5) [20.3–120]
5113.6 (1.6) [1–6]286.4 (134.5) [80–480]9.7 (4.5) [3–16]360.0 (81.7) [192–400]80.4 (31.2) [20–120]
654.2 (1.9) [1–6]368.0 (170.1) [80–500]9.9 (5.5) [3–15.4]400.0 (0.0) [400–400]92.0 (42.5) [20–125]
  1. aMaximun total dose/weight recommended in previous articles (16 U/kg, not exceeding 400 U); bTotal dose injected/maximum total dose; cn = 51; dn = 32